Director Judith V. Klimovsky filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, at a price of $0.

Key Highlights

  • Reporting person: Judith V. Klimovsky, Director of BIO-TECHNE Corp (NASDAQ:TECH)
  • Transaction: Acquisition (Code A) of 2,750 shares of common stock on October 29, 2026, at a price of $0
  • Post-transaction ownership: 6,532 shares of common stock held directly following the reported transaction
  • New stock option: A stock option (right to buy) for 3,777 shares of common stock at an exercise price of $60.96, exercisable from October 29, 2026, with an expiration date of October 30, 2035
  • Existing options: Klimovsky also holds options for 1,610 shares at $73.46 (exercisable since October 24, 2024, expiring May 1, 2034) and 3,511 shares at $68.37 (exercisable since October 24, 2025, expiring October 24, 2034)
  • Filing agent: The form was signed by Andrew Nick as Attorney-in-Fact for Judith V. Klimovsky pursuant to a previously filed Power of Attorney

BIO-TECHNE Director Klimovsky Reports October 29, 2026 Share Acquisition and Option Holdings

According to the Form 4 filing submitted on November 2, 2026, Judith V. Klimovsky, a Director of BIO-TECHNE Corp (NASDAQ:TECH), reported an acquisition of 2,750 shares of the company's common stock on October 29, 2026. The transaction was coded "A" (acquired) and carried a reported price of $0. Following this transaction, the filing states that Klimovsky directly owns 6,532 shares of BIO-TECHNE common stock.

The filing also discloses three stock options held by Klimovsky, all classified as direct ownership. The most recent, reported with a transaction date of October 29, 2026, grants the right to buy 3,777 shares of common stock at an exercise price of $60.96 per share; this option becomes exercisable on October 29, 2026, and expires on October 30, 2035. Two previously existing options are also listed: one covering 1,610 shares at an exercise price of $73.46, exercisable since October 24, 2024, and expiring May 1, 2034; and another covering 3,511 shares at an exercise price of $68.37, exercisable since October 24, 2025, and expiring October 24, 2034.

The form was filed as an individual report by one reporting person. It was signed by Andrew Nick as Attorney-in-Fact for Judith V. Klimovsky, pursuant to a Power of Attorney filed previously, and bears a signature date of November 2, 2026. No amendment date is indicated, and the filing does not check the box indicating a Rule 10b5-1(c) written trading plan.

What Was Disclosed

The filing reports Director Judith V. Klimovsky's acquisition of 2,750 BIO-TECHNE common shares at $0 on October 29, 2026, bringing her direct holdings to 6,532 shares, along with three stock options covering a combined 8,898 shares at varying exercise prices and expiration dates.